Page 10 of 439: studies 91 to 100 of 4,389, newest first. Back to the psilocybin overview
Mental Health Weekly August 21, 2026 Valerie A. Canady
Given the growing interest in psychedelic‐assisted therapies, questions remain about how such services perform outside controlled clinical trials. A new JAMA Network Open study offers an early look at the risks and benefits of Oregon's state‐regulated psilocybin program, which researchers describe as the first study of its kind in the nation.
Acad Forensic Pathol August 21, 2026
Complex Fatal Self-Harm Under Psilocybin Intoxication: Suicidal Manner of Death or Not?
bioRxiv August 20, 2026 Ilknur Kayikcioglu Bozkir, Ryan Lashin, Tiecheng Liu et al. preprint
Psilocybin is a psychedelic which has been shown to induce neural plasticity through activation of intracellular serotonergic 5-HT2A receptors. It also produces brain-wide changes in structural and functional connectivity and holds promise as a therapeutic compound for treating anxiety and depression. Despite links between psilocybin-induced plasticity, the psychedelic experience, and reduction...
Lynchburg Journal of Medical Science August 20, 2026 Rachel N Clark
The purpose of this review is to evaluate the possible benefits of using psilocybin (C12H17N2O4P), a naturally occurring psychoactive compound found in certain species of mushrooms, in the treatment of multiple forms of mental illness and substance use disorders, either as monotherapy or in conjunction with traditional psychiatric medications. The compound has high affinity for several...
medRxiv August 19, 2026 Harland V. Harrison, Maxence Gaillard, Ryan Cook et al. preprint
Introduction: In 2020, Oregon became the first US state to legalize state-regulated psilocybin services. This study aims to examine: 1) the clinical and demographic characteristics, 2) psilocybin use motivations, and 3) differences in preparedness among patients seeking care in a Oregon- based pilot consult service specializing in psilocybin risk reduction. Methods: This retrospective chart...
bioRxiv August 19, 2026 D. Momi, Yasmeen Nahas, D. Wyrick et al. preprint
Psilocybin produces rapid and lasting therapeutic effects, yet how 5-HT2A receptor activation reshapes brain-wide circuit dynamics during acute drug administration remains poorly understood. Using simultaneous multi-region Neuropixels recordings of 46,360 single units from 35 mice, together with scalp electroencephalography (EEG), pupillometry, and locomotion monitoring, we provide a...
Frontiers in Psychiatry August 19, 2026 Jeni Page, Alexandra Moore, Bridget E. Hawkins et al.
IntroductionMicrodosing psilocybin magic mushrooms (MM) and truffles has grown in popularity, but the evidence supporting reported benefits remains poorly characterized. The purpose of this systematic review was to synthesize the existing literature on microdosing psilocybin MM and truffles in adults to determine reported health effects and perceived benefits, motivations for use, dosing...
August 18, 2026 Ximena A. Levander, Ryan Cook, Devin Gregoire et al. preprint
There has been growing public and research interest in the use of psychedelics, particularly psilocybin. There is limited data on psilocybin use patterns, motivations for use, safety, and efficacy in older adults (>or= 60 years old) as older adults tend to be excluded from clinical trials. However, older adults may seek out psilocybin through state-regulated or naturalistic settings for...
Journal of Psychopharmacology August 17, 2026 Lana Strika-Bruneau, Chérine Elhssaini, Baptiste Fauvel et al.
Background: Psychedelic-assisted psychotherapy (PAP) shows promise for substance use disorders (SUDs), yet the respective contributions of pharmacological, experiential, psychotherapeutic, and contextual factors remain insufficiently understood. Objective: To synthesize contemporary clinical evidence on PAP for SUDs, with particular attention to therapeutic frameworks, dosing strategies,...
bioRxiv : the preprint server for biology August 13, 2026 David S Jacobs, Alejandro Torrado Pacheco, Randall J. Olson et al. preprint
Emerging clinical research with psilocybin highlights the value of the psychedelic experience on successful treatment of a multitude of psychiatric disorders. While the psychedelic trip or clinical support procedures cannot be modeled in rodents, neural processes critical to meta-learning and flexible modification of previously learned strategies can be quantified during psilocybin exposure....